C4 Therapeutics
About C4 Therapeutics
C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T’s internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder and CEO: Marc Cohen
Founders: Ken Anderson, Marc Cohen, Jay Bradner and Nathanael Gray
CSO: Andy Phillips
CAO: Andrea Armstrong
CBO: Tom Needham
JOBS:
Please click here for C4 job opportunities.
FOLLOW C4 THERAPEUTICS:
Tweets by C4 Therapeutics
25 articles with C4 Therapeutics
-
C4 Therapeutics Appoints Glenn Dubin to Board of Directors
4/5/2019
He brings three decades of experience leading global, multi-strategy organizations across a wide range of industries to C4T’s Board.
-
C4 Therapeutics Appoints Adam Crystal, M.D., Ph.D. as Chief Medical Officer
3/14/2019
C4 Therapeutics (C4T) today announced the appointment of Adam Crystal M.D., Ph.D. as Chief Medical Officer. Dr. Crystal will oversee C4T’s activities relating to the clinical development of the company’s pipeline of targeted protein degraders.
-
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
-
C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche
1/4/2019
C4 Therapeutics announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology
-
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
-
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
-
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
C4 Therapeutics Announces Promotion of Stewart Fisher, Ph.D. to Chief Scientific Officer
5/3/2018
C4 Therapeutics (C4T) today announced that Stewart Fisher, Ph.D. has been promoted to Chief Scientific Officer
-
C4 Therapeutics Announces Appointment of Andrew Phillips, Ph.D. as President and Chief Executive Officer
5/3/2018
C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been appointed as President and Chief Executive Officer. Dr. Phillips has been leading C4T’s scientific efforts as Chief Scientific Officer since January 2016 and assumed corporate leadership responsibilities with his added appointment as President in September 2016
-
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
-
C4 Therapeutics Expands Management Team with Appointment of Ron Kaiser as Chief Financial Officer
11/14/2017
He also served on C4T’s Board of Directors from January 2016 until October 2017.
-
C4 Therapeutics Appoints Michael Kim As Vice President Of Business Development
8/11/2017
-
C4 Therapeutics Announces The Addition Of Leading Researchers In Hematology-Oncology To Scientific Advisory Board
7/27/2017
-
Booming C4 Therapeutics to Move Out of Pricey Kendall Square Next Year
7/12/2017
-
Google's Mysterious Biotech Calico Forms a Rare Deal With C4 Therapeutics
3/27/2017
-
What You Need to Know About C4 Therapeutics
1/11/2017
-
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
-
C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise In Therapeutics And The Ubiquitin-Proteasome System
11/17/2016
-
C4 Therapeutics Announces World-Class Scientific Advisory Board With Expertise In Therapeutics And The Ubiquitin-Proteasome System
11/17/2016